LY-3473329

Eli Lilly's experimental drug lepodisiran demonstrated up to 95% reduction in lipoprotein(a) levels with a single 400mg dose in midstage trials, potentially addressing a significant cardiovascular risk factor prevalent in South Asian populations.

Merck has secured exclusive global rights (excluding Greater China) to HRS-5346, an investigational oral small molecule Lipoprotein(a) inhibitor currently in Phase 2 trials in China.

2024 marked significant progress in lipid management, with notable advancements in the treatment of familial chylomicronemia syndrome (FCS) and lipoprotein(a) (Lp(a)) management. However, the year also saw challenges to the 'HDL hypothesis', highlighting the complexity of lipid-related cardiovascular disease prevention. Key developments included FDA approvals of novel therapies and promising results from clinical trials targeting triglycerides and Lp(a).

Cyclarity Therapeutics has initiated a Phase 1 clinical trial in Australia to evaluate UDP-003, a drug targeting atherosclerosis.

The European Commission has approved Pfizer's Hympavzi (marstacimab) for hemophilia A and B treatment, based on positive Phase III BASIS study data.